Green Cross Corporation (006280.KS)
- Business Wire
GC Biopharma Reports Q1 2022 Results
YONGIN, South Korea, May 02, 2022--GC Biopharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 31 March 2022.
- Business Wire
GC Biopharma Concludes Agreement With Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
YONGIN, South Korea & VANCOUVER, Canada, April 28, 2022--GC Biopharma (006280.KS) and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, today announced that they have entered into a Development and Option agreement for Acuitas’ LNP technology.
- Business Wire
GC Biopharma Celebrates ‘World Hemophilia Day’
YONGIN, South Korea, April 17, 2022--GC Biopharma (006280.KS), a South Korean biopharmaceutical company, takes part in a campaign to celebrate World Hemophilia Day.
